WASHINGTON – For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as ...

Hims & Hers is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs—including popular weight loss medications—as part of the Trump ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

The renowned health and wellness platform, Hims & Hers Health, Inc.’s HIMS, business model links virtual consultations ...

Hims & Hers HealthHIMS is Wednesday's IBD Stock Of The Day. After returning to the IBD 50, Hims stock is making a second attempt at a breakout since late July. The telehealth giant announced its ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

The Food and Drug Administration building is seen on Dec. 10, 2020, in Silver Spring, Md. (AP Photo/Manuel Balce Ceneta, File) WASHINGTON (AP) — For the first time, federal health officials are taking ...